Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

Hair loss treatments have not advanced since 2018, with finasteride, minoxidil, and RU58841 still being the main options. A permanent cure is unlikely due to the profitability of ongoing treatments.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

A new hair loss treatment shows promise in mice but is unproven in humans. Effective treatments include finasteride and minoxidil.

Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

The user is experiencing diffuse hair loss despite using finasteride and dutasteride and is considering adding minoxidil, microneedling, or RU58841. They are also thinking about increasing the dutasteride dose or opting for a hair transplant, while being cautious about side effects.

Finasteride, dutasteride, and minoxidil can help prevent or slow hair loss for many, though results vary. The dermatologist's claim that no medication works is incorrect, as these treatments are effective for some individuals.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

A 30-year-old man shared his positive experience with hair regrowth using Regenera Activ, topical Dutasteride, Minoxidil, and PRP over 12 weeks. He plans to continue with injectable Dutasteride and emphasizes the importance of starting treatment early to combat hair loss.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

Diet and lifestyle changes can reduce hair shedding but won't regrow hair lost to genetic male pattern baldness. Treatments like finasteride and dutasteride are necessary for significant hair regrowth.

The user has been dealing with hair loss for 10 years, worsened by psoriasis, and uses minoxidil and finasteride. They seek advice on managing psoriasis and hair loss, with suggestions to see a dermatologist, try different shampoos, and be patient.

Various treatments for hair loss include minoxidil injections, finasteride, dutasteride, microneedling, Nizoral shampoo, and supplements like vitamin D and biotin. Additional methods mentioned are red light therapy, scalp massages, lifestyle changes, and hair transplants.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.

A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.

Microneedling is supported by research as an effective adjuvant treatment for hair loss, especially when combined with Minoxidil or Finasteride, with minimal side effects if done properly. Concerns about long-term safety and potential risks like infection or fibrosis remain, but many users report positive results.

Minoxidil is harmful to pets, especially cats, if they contact it. Users recommend switching to oral minoxidil or taking precautions like washing hands and using head coverings to prevent exposure.

A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

Exosomes are being discussed as a potential hair loss treatment, with some users skeptical about their effectiveness and stability. There is interest in different types of exosomes, including those derived from centella asiatica, and comparisons are made to other treatments like finasteride.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.